Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast, Advisory, Business Update

Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 30, 2024. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Fourth Quarter and Full Year 2023 Performance Report, to be issued that morning.

To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call.

You can also listen to the conference call by dialing either 800-456-4352 in the United States and Canada or 785-424-1086 outside of the United States and Canada. The passcode is "84692".

The transcript and webcast replay of the call will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live conference call and will be accessible for at least 90 days.

About Pfizer: Breakthroughs That Change Patients' Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice: The webcast may include forward-looking statements about, among other things, our anticipated operating and financial performance, including financial guidance and projections, reorganizations, business plans, strategy and prospects; our Environmental, Social and Governance (ESG) priorities, strategy and goals; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, potential pricing and reimbursement, potential market dynamics, size and utilization rates, growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities; and our ability to successfully capitalize on growth opportunities; manufacturing and product supply; our ongoing efforts to respond to COVID-19, including our COVID-19 products; our expectations regarding the impact of COVID-19 on our business, operations and financial results; and other statements about our business, operations and financial results, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. A description of these risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

The forward-looking statements in the webcast speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.

Category: Finance


These press releases may also interest you

at 16:14
ECC Ventures 6 Corp. (the "Company" ) is pleased to announce that Scott Ackerman has been appointed as a director of the Company, replacing Nathan Durno, who has resigned as a director of the Company. In addition, an aggregate of 1,800,000...

at 15:30
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Roblox Corporation between November 15, 2023 and May 8, 2024, both dates inclusive (the "Class Period"), of the important August 12, 2024 lead plaintiff...

at 14:50
The Alberta Electric System Operator (AESO) Board announced today that Michael Law, President and Chief Executive Officer, will leave the organization, effective August 1, 2024. Law first joined the AESO in 2009 as Vice-President, Operations and was...

at 14:19
Jennifer Mersereau, Senior Partner, Co-Founder & COO, Hamilton ETFs, Patrick Sommerville, Senior Partner, Head of Business Development, Hamilton ETFs, and their team joined Keith Wu, Head, Exchange Traded Products, Toronto Stock Exchange , to open...

at 14:03
New research insights from Info-Tech Tech Research Group will equip food and beverage manufacturers with essential strategies for embracing digital transformation. The global research and advisory firm explains that the industry can significantly...

at 13:50
Canadian General Investments, Limited (CGI)  (LSE: CGI) reports on an unaudited basis that its net asset value per share (NAV) at June 30, 2024 was $62.50, resulting in year-to-date and 12-month NAV returns, with dividends reinvested, of 13.3% and...



News published on and distributed by: